| Title: | Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer |
| Authors: | Watanabe, Kazunori Browse this author |
| Nakamura, Toru Browse this author →KAKEN DB |
| Kimura, Yasutoshi Browse this author |
| Motoya, Masayo Browse this author |
| Kojima, Shigeyuki Browse this author |
| Kuraya, Tomotaka Browse this author |
| Murakami, Takeshi Browse this author |
| Kaneko, Tsukasa Browse this author |
| Shinohara, Yoshihito Browse this author |
| Kitayama, Yosuke Browse this author |
| Fukuda, Keito Browse this author |
| Hatanaka, Kanako C. Browse this author |
| Mitsuhashi, Tomoko Browse this author |
| Pittella-Silva, Fabio Browse this author |
| Yamaguchi, Toshikazu Browse this author |
| Hirano, Satoshi Browse this author →KAKEN DB |
| Nakamura, Yusuke Browse this author |
| Low, Siew-Kee Browse this author |
| Keywords: | cell-free DNA |
| circulating tumor DNA |
| liquid biopsy |
| pancreatic cancer |
| tumor-informed approach |
| neoadjuvant therapy |
| next-generation sequencing |
| cancer prognosis |
| Issue Date: | Oct-2022 |
| Publisher: | MDPI |
| Journal Title: | International Journal of Molecular Sciences |
| Volume: | 23 |
| Issue: | 19 |
| Start Page: | 11521 |
| Publisher DOI: | 10.3390/ijms231911521 |
| Abstract: | Pancreatic cancer is one of the cancers with very poor prognosis; there is an urgent need to identify novel biomarkers to improve its clinical outcomes. Circulating tumor DNA (ctDNA) from liquid biopsy has arisen as a promising biomarker for cancer detection and surveillance. However, it is known that the ctDNA detection rate in resected pancreatic cancer is low compared with other types of cancer. In this study, we collected paired tumor and plasma samples from 145 pancreatic cancer patients. Plasma samples were collected from 71 patients of treatment-naive status and from 74 patients after neoadjuvant therapy (NAT). Genomic profiling of tumor DNA and plasma samples was conducted using targeted next-generation sequencing (NGS). Somatic mutations were detected in 85% (123/145) of tumors. ctDNA was detected in 39% (28/71) and 31% (23/74) of treatment-naive and after-NAT groups, respectively, without referring to the information of tumor profiles. With a tumor-informed approach (TIA), ctDNA detection rate improved to 56% (40/71) and 36% (27/74) in treatment-naive and after-NAT groups, respectively, with the detection rate significantly improved (p = 0.0165) among the treatment-naive group compared to the after-NAT group. Cases who had detectable plasma ctDNA concordant to the corresponding tumor showed significantly shorter recurrence-free survival (RFS) (p = 0.0010). We demonstrated that TIA improves ctDNA detection rate in pancreatic cancer, and that ctDNA could be a potential prognostic biomarker for recurrence risk prediction |
| Type: | article |
| URI: | http://hdl.handle.net/2115/87396 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
